GlassScriptPhysician profile
Kelsey Richmond
NPI 1093238479
$3,676.49
in general payments reported to CMS, 2019-2025
33 companies · $947 in 2025
The $947 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $721 · 2023: $748 · 2024: $859 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,536 · Education: $19.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,535.55 |
| Education | $19.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $565.52 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $415.06 | 2022-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $367.57 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $322.85 | 2021-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $238.61 | 2022-2024 | Lupkynis |
| Travere Therapeutics, INC. | $233.76 | 2022-2025 | |
| Amgen INC. | $214.45 | 2021-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $191.93 | 2021-2025 | |
| Cordis US Corp. | $125.00 | 2025 | S.M.A.R.T. Control |
| Glaxosmithkline, LLC. | $99.58 | 2021-2024 | Benlysta |
| Mallinckrodt Hospital Products INC. | $98.60 | 2021-2024 | Acthar |
| Akebia Therapeutics INC | $87.91 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $63.80 | 2022-2024 | Ultomiris |
| Vifor Pharma, INC. | $60.57 | 2022-2025 | Veltassa |
| Apellis Pharmaceuticals, INC. | $53.56 | 2025 | Empaveli |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $53.36 | 2024-2025 | Ibsrela |
| Novo Nordisk INC | $46.79 | 2024-2025 | Ozempic, Rybelsus |
| Recor Medical INC | $46.10 | 2025 | Paradise Ultrasound Renal Denervation System |
| Alpha Cognition USA, INC. | $45.97 | 2025 | Zunveyl |
| Daiichi Sankyo INC. | $37.68 | 2021-2024 | Injectafer |
| Recordati_rare_diseases_inc. | $35.29 | 2021 | |
| Opko Pharmaceuticals, LLC | $35.01 | 2022-2023 | Rayaldee |
| Lilly USA, LLC | $34.91 | 2024 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.53 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $24.81 | 2023 | Prehevbrio |
| Novartis Pharmaceuticals Corporation | $24.03 | 2023 | |
| Ani Pharmaceuticals, INC. | $22.13 | 2022 | |
| Renalytix Ai, INC. | $20.65 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Scpharmaceuticals INC. | $18.45 | 2025 | |
| Genzyme Corporation | $17.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.28 | 2025 | Jardiance |
| Pharmacosmos Therapeutics INC. | $15.93 | 2022 | |
| Horizon Therapeutics Plc | $14.22 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Richmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.